A Phase 3, Open-Label, Randomised, Multicentre Study Comparing AZD0120, A Dual-Targeting Autologous Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA And CD19, Versus Standard Regimens In Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)